OXvax Ltd. is a spin out company from the University of Oxford focused on the development of an advanced next generation dendritic cell vaccine platform for the treatment of solid tumour cancers.
The Company’s technology is based on intellectual property from the Fairchild laboratory at the Sir William Dunn School of Pathology and exploits induced pluripotent stem cells (iPSC) as a novel source of CD141+ dendritic cells (DC), a novel proprietary subset whose unique properties make them attractive candidates for cancer immunotherapy.
OXvax is located in Oxford, United Kingdom and is led by its founders. The company is fast tracking its development programme, leveraging resources at Oxford University and working in partnership with external contract development and manufacturing organisations.
If you require any further information, please feel free to contact us using info@oxvax.uk.
FOUNDERS
Paul J Fairchild - Chairman Scientific Advisory Board
Associate Professor of the Immunobiology of Stem Cells, Fellow in Medicine at Trinity College and founding Director of the Oxford Stem Cell Institute. Paul obtained his DPhil from the University of Oxford and has conducted world leading research at both Oxford and Cambridge Universities that has led to first-in-man clinical trials for the treatment of non-small cell lung cancer. He serves on the SAB of the UK Government’s Cell and Gene Therapy Catapult.
Tim Davies - Head of Laboratory Operations
Research scientist with over 35 years’ experience in the field of stem cell biology and immunology. Tim trained at Cardiff University and Birkbeck College, London before joining Sir Richard Gardner’s laboratory at Oxford for which he served as research manager for more than 20 years. He has been instrumental in developing the protocols for derivation and differentiation of iPSC, on which the OXvax technology is based.
Marcelo Bravo - Chief Executive Officer
Serial entrepreneur with international experience in major blue chip companies as well as a number of start-ups bringing academic research-based innovation to market. Marcelo has taken two companies public to the AIM market, raising over £45m, mostly from institutional investors but also from family offices and HNWs. Marcelo worked with Paul and Tim on the development of OXvax as part of his work towards an MSc in Experimental Therapeutics at Oxford.
The founders with Shinya Yamanaka in Oxford, 2019. Professor Yamanaka won the 2012 Nobel Prize for Medicine jointly with Sir John Gurdon for the discovery that mature cells can be reprogrammed to pluripotent stem cells. The discovery of induced pluripotent stem cells has opened unprecedented opportunities in disease modelling and in regenerative medicine and underpins the OXvax technology platform.
INVESTORS
Lead Compass Investment is a Korean based biotech venture capital firm focusing on supporting breakthrough life science companies to solve important healthcare needs. Lead Compass brings together talented entrepreneurs with experience in science, research, and development to translate scientific discoveries into high-impact medicines.
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. Evotec operates worldwide and the Company’s headquarters are located in Hamburg, Germany.